

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: Blueberries Medical Corp. (the "Company or "Issuer").

Trading Symbol: BBM

Number of Outstanding Listed Securities: 142,996,446
Date: **April 2021**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Blueberries Medical Corp. ("Blueberries") is executing its strategy to become a large-scale producer and processor of naturally grown premium quality cannabis and a leading Latin American supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products with its primary operations situated in the Bogotá Savannah in central Colombia.

The Company has commenced sales of its proprietary cultivars approved by the Colombian Institute of Agriculture ("ICA"). Blueberries has entered into multiple sales agreements to distribute its proprietary genetics to licensed producers located in Bogota Savannah, the region where the Company operates. Under the agreements, the Company will leverage contract growers to produce the Company's registered non-psychoactive cannabidiol ("CBD") strains approved by ICA. These proprietary cultivars were developed and tested by the Company's agronomic team and optimized for growth in the local climate.

Production from contract growers will be processed at the Company's extraction facility under arrangements whereby Blueberries will retain a certain portion of the extracted product for resale as compensation for these services. Such arrangements provide the Company with premium extracts without the associated cultivation capital expenditures and related risks.

2. Provide a general overview and discussion of the activities of management.

On April 30th, the Issuer announced its financial results for the year ended December 31, 2020. Blueberries has filed its audited consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries' profile at www.sedar.com. All financial information is reported in Canadian dollars, unless otherwise indicated.

Financial Highlights Commentary:

Revenues- Blueberries commenced commercial operations in late Q2, 2020 with sales of cloned cuttings of its cultivars to associate growers (\$59,308) and introductory sales of its cosmetics products (\$6,670).

Pre-operating expenses- Since the Company is in early stages of commercial operations, material operational costs are included under pre-operating expenses, which are non-capital expenditures relating to Blueberries' cannabis cultivation and extraction operations. During 2020, due to COVID-19, the company implemented voluntary salary reductions for personnel in management positions, which is reflected in the lower pre-operating expenses in the year.

Highlights

- Early in 2020, Blueberries implemented extensive cost saving measures of reducing administrative, capital, and operational expenditures and preserving working capital to optimize its cost structure and focus on revenue bringing activities.
- Due to the ongoing impact of the coronavirus ("COVID-19") pandemic, Blueberries is continuing its cost saving measures until significant revenues from sales commence.

- On November 30, 2020 Blueberries completed the acquisition of BBV Labs Inc. ("BBV Labs"), a corporation that owns 75% of the rights to a joint venture with an Argentinian state-owned company.

- On January 19, 2021, Blueberries completed a private placement for aggregate gross proceeds of C\$1,000,000. In connection with the private placement, Facundo Garretón was named Chairman and Interim Chief Executive Officer. Previous directors Christian Toro, Fabio Valencia Cossio, Dr. Andres Vidal, Francisco Sole, Matthew Bajurny and Paola Castañeda have all stepped down from the Board, with the new Board being comprised of the following four directors: Facundo Garretón, Patricio Villalba, Catherine Lathwell and Sebastian Hochbaum. The Audit Committee of the Board was reconstituted to include Catherine Lathwell, Patricio Villalba and Facundo Garreton.

- On February 16, 2021, Blueberries appointed Mr. José María Forero, the former Global Head of B2B of Clever Leaves Holdings Inc. as President of Latin American Operations.

- On March 15, 2021, BBSAS entered into an agreement to supply premium, formulated cannabis oil to Futura Farms, a licensed distributor serving the Peruvian market.

- On March 24, 2021, Blueberries signed a framework agreement with YVY Life Sciences for mutual development of strains and genetics in Colombia and exporting dry cannabis flower of mutual strains from Uruguay.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

N/A

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

N/A

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2021.

Ian D. Atacan
Name of Director or Senior Officer

"Ian D. Atacan"
Signature

Chief Financial Officer
Official Capacity

Issuer Details Name of Issuer Blueberries Medical Corp.	For Month End April 2021	Date of Report YY/MM/DD 2021/05/04
Issuer Address 885 West Georgia Street, Suite 2200, HSBC Building		
City/Province/Postal Code Vancouver, BC V6C 3E8	Issuer Fax No.	Issuer Telephone No.
Contact Name Ian Atacan	Contact Position CFO	Contact Telephone No. (416) 562-3220
Contact Email Address iatacan@blueberriesmed.com	Web Site Address www.blueberriesmed.com	